Bedaquiline: Finding the pores on the pot

European Respiratory Journal

Volumn 46, Issue 1, 2015, Pages 289-291

  Salfinger, Max ^a   Migliori, Giovanni Battista ^b  

^a DEPARTMENT OF MEDICINE   (United States)

^b IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; DELAMANID; CLOFAZIMINE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; DRUG MONITORING; HEALTH CARE POLICY; HUMAN; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; WORLD HEALTH ORGANIZATION; ANTIBIOTIC RESISTANCE; GENETICS; MUTATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CLOFAZIMINE; DIARYLQUINOLINES; DRUG RESISTANCE, BACTERIAL; HUMANS; MUTATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84937440705     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00030915     Document Type: Note

References (11)

1. Salfinger M, Migliori GB. Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending. Eur Respir J 2015; 45: 317-321.
2. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993.
3. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
4. World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva, World Health Organization, 2013. Available from: http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482-eng.pdf
5. World Health Organization. Policy Implementation Package For New TB Drug Introduction. Geneva, World Health Organization. 2014. Available from: http://www.who.int/tb/PIPnewTBdrugs.pdf
6. World Health Organization. The use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis. Interim Policy Guidance. Geneva, World Health Organization. 2014. Available from: http://apps.who.int/iris/bitstream/10665/137334/1/WHO-HTM-TB-2014.23-eng.pdf?ua=1
7. Salfinger M, Somoskövi A. Multidrug-resistant tuberculosis and bedaquiline. N Engl J Med 2014; 371: 2435-2436.
8. Migliori GB, Lienhardt C, Weyer K, et al. Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. Eur Respir J 2014; 44: 1412-1417.
9. Blasi F, Dara M, van der Werf MJ, et al. Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. Eur Respir J 2013; 41: 491-494.
10. D'Ambrosio L, Tadolini M, Dupasquier S, et al. ERS/WHO Tuberculosis Consilium: reporting of the initial 10 cases. Eur Respir J 2014; 43: 286-289.
11. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.